27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
In propensity-matched comparator analyses, during the 2 year time-period from treatment initiation, semaglutide was associated with broadly lower neuropsychiatric event risk than metformin, SGLT2 inhibitors, and DPP-4 inhibitors. 4 key findings →
Design: longitudinal study Participants: 63,215 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Long-term metformin treatment is associated with a reduced risk of dementia and better memory performance among persons with pre-diabetes or T2D. Longer follow-up with more dementia cases is needed to confirm our findings. 5 key findings →
Design: longitudinal study Participants: 1,483 Evidence: high
Full summary, score breakdown and related studies → Original source
Among 2,577,000 Veterans (mean age, 63 years; 4.5% female; 65% White; 15% Black), 10% initiated ARBs and 90% initiated ACEIs. 5 key findings →
Design: longitudinal study Participants: 2,577,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
DESI is a robust, fully automated MRI biomarker that sensitively detects CSF redistribution characteristic of DESH in iNPH. 1 key finding →
Design: longitudinal study Participants: 1,032 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Greater diversity of social participation was associated with better long-term cognitive maintenance among older adults with hypertension and/or diabetes. 5 key findings →
Design: longitudinal study Participants: 547 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Biological definitions of neuronal α-synuclein disease are advancing diagnosis beyond traditional clinical syndromes, but the trajectories preceding dementia and the influence of concomitant Alzheimer pathology remain uncertain. 3 key findings →
Design: longitudinal study Participants: 1,543 Evidence: moderate
Full summary, score breakdown and related studies → Original source
When stable individual differences are accounted for, depressive symptoms emerge as a stronger within-person temporal predictor of cognitive decline than physical activity. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Most plasma proteomic studies in Alzheimer’s disease (AD) compare cases and controls cross-sectionally, leaving unresolved which AD-associated proteins mark diagnostic states and which are linked to disease progression. 5 key findings →
Design: longitudinal study Participants: 13,449 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the English Longitudinal Study of Ageing (ELSA: n=9,473, median age 64, range 50 to ≥90), linear mixed-effects models examined age-specific differences in cognitive change (recall and fluency) associated with sleep duration, difficulty falling asleep, nocturnal awakenings, incorporating sleep-by-age-by-time interactions, with initial adjustment for sociodemographic factors and further adjustment for health and lifestyle factors. 5 key findings →
Design: cohort study Participants: 9,473 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of total 8,321 participants, 24.88% (2,070) developed cognitive impairment during a 10-year follow-up. 5 key findings →
Design: longitudinal study Participants: 8,321 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Controlling for baseline differences, treatment of OSA improved delayed recall and may reduce the slope of memory decline in Alzheimer’s disease and vascular dementia. 3 key findings →
Design: cohort study Participants: 86 Evidence: moderate
Full summary, score breakdown and related studies → Original source
All Big Five domains had prospective associations with multiple dementia risk factors and with cognitive impairment, cognitive function, and self-reported memory. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age-related hearing loss is a leading modifiable risk factor for dementia and is increasingly recognized as a non-motor feature of Parkinson’s disease (PD). 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Absolute BPV was associated with mortality, and DBP and MAP variability with overall stroke, after accounting for glycemic status and mean blood pressure. 5 key findings →
Design: prospective cohort Participants: 57,611 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Seasonally normalized 25(OH)D identifies a reproducible state of systemic vulnerability while reducing exposure misclassification caused by calendar timing of measurement. 5 key findings →
Design: longitudinal study Participants: 412,020 Evidence: moderate
Full summary, score breakdown and related studies → Original source
CAD was not associated with global or domain-level neurocognitive performance. 5 key findings →
Design: cohort study Participants: 512 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher educational attainment is associated with steeper measured cognitive decline among older adults in India, but whether this association is uniform across the country is unknown. 2 key findings →
Design: longitudinal study Participants: 2,510 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive staging and everyday function are not interchangeable. 1 key finding →
Design: retrospective cohort Participants: 202,508 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this bvFTD cohort, structural volumes of key frontotemporal and perisylvian regions did not predict behavioral or language impairments after correction for multiple comparisons. 3 key findings →
Design: longitudinal study Participants: 87 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Anxiety localizes to a brain circuit resembling the AD-related atrophy network, is consistent across the AD continuum and may extend beyond AD. 5 key findings →
Design: longitudinal study Participants: 1,775 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We tested whether, across sexes, alignment with female-typical, rather than male-typical, patterns of neural functional connectivity (FC) would relate to a diagnosis (adolescent sample) or severity of symptoms (adult sample) associated with internalizing disorders, which tend to be more often diagnosed in females. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
By comparing these unsupervised representations to a depression-labelled source corpus, one cluster demonstrated mathematical proximity (measured via cosine similarity in a shared latent space) to the source depression centroid. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Newly diagnosed postoperative depression was associated with increased dementia risk, particularly in patients aged < 65 years, supporting prospective evaluation as a potential marker of long-term cognitive risk. 4 key findings →
Design: cohort study Participants: 424,637 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Launched in 2010 by the National Institutes of Health, the Human Connectome Project (HCP) represents a foundational initiative in systems neuroscience, designed to map the structural and functional architecture of the human brain. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher UGS coverage was associated with a lower risk of incident AD among older adults in urban South Korea. 4 key findings →
Design: cohort study Participants: 95,822 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →